Giles A R, Nesheim M E, Hoogendoorn H, Tracy P B, Mann K G
Br J Haematol. 1982 Jul;51(3):457-68. doi: 10.1111/j.1365-2141.1982.tb02803.x.
A stroma free platelet lysate supernatant (PLS) was prepared by repeatedly freezing and thawing a human platelet suspension separated from platelet rich plasma by gel filtration. The material was potently thrombogenic in a stasis model in rabbits, but only when combined with a purified preparation of factor Xa. The dose of factor Xa used was not thrombogenic when given alone. Initial evaluation suggested the presence of a factor V activator when PLS shortened the clotting time of normal but not a V deficient plasma. Subsequent evaluation, in a system employing purified components of the prothrombinase complex and a marker of thrombin generation, dansyl-arginine-N-(3-ethyl-1,5-pentanediyl)amide (DAPA), failed to confirm the presence of a factor V activator. Further evaluation in this system demonstrated that the procoagulant activity related to the content of coagulant-active phospholipid. Thin layer chromatography confirmed the presence of phospholipids known to have coagulant activity. These components were isolated by a lipid extraction procedure and the phospholipid replacing activity in the in vitro assay with DAPA was quantitatively retained. The extracted material was non-thrombogenic in vivo but augmented the thrombogenicity of a purified preparation of Xa.
通过对经凝胶过滤从富含血小板血浆中分离出的人血小板悬液进行反复冻融,制备了无基质血小板裂解物上清液(PLS)。该物质在兔的血流淤滞模型中具有很强的致血栓形成作用,但仅在与纯化的Xa因子制剂联合使用时才会出现这种情况。单独给予所用剂量的Xa因子时并无致血栓形成作用。初步评估表明,当PLS缩短正常血浆而非V因子缺乏血浆的凝血时间时,提示存在V因子激活剂。随后,在一个使用凝血酶原酶复合物的纯化成分和凝血酶生成标志物丹磺酰精氨酸-N-(3-乙基-1,5-戊二酰)酰胺(DAPA)的系统中进行评估,未能证实存在V因子激活剂。在该系统中的进一步评估表明,促凝活性与具有凝血活性的磷脂含量有关。薄层色谱法证实存在已知具有凝血活性的磷脂。通过脂质提取程序分离出这些成分,并且在使用DAPA的体外试验中,磷脂替代活性被定量保留。提取的物质在体内无致血栓形成作用,但增强了纯化的Xa制剂的致血栓形成性。